CEBU, Philippines -- Singapore-based venture capital company Vickers Venture Partners has led a $13.2 million Series B funding in SiSaf, a U.K.-headquartered biotech startup that develops drugs using what it calls bio-courier technology, according to an announcement.
The funding was also matched by Future Fund, a U.K. governmental fund that supports innovative businesses currently affected by COVID-19.
Founded in 2006, SiSaf is a commercial-stage biopharmaceutical company headquartered in the city of Guilford. It has research labs, manufacturing and bio-analytical facilities.
It is the creator of bio-courier technology, a non-viral, hybrid carrier system that enables the targeted delivery of therapeutic small interfering Ribonucleic acids (siRNA).
The startup says it will use the fresh funding to accelerate its RNA therapeutics programs to treat rare and therapeutically neglected genetic conditions of bones and the eye.
Some of the Series B cash will be used to expand the company's pipeline across multiple debilitating autosomal dominant disorders.
"This funding will speed up the translation of top scientific research into safe, effective and accessible treatments for patients with no specific treatment options currently available to them," said Suzanne Saffie-Siebert, the company's founder and CEO.
Vickers Venture Partners, the lead investor in the funding round, is a global VC company focused on early-stage investments in technological and geographical megatrends.
In March, it raised $200 million for its $500 million sixth fund, one of Southeast Asia's largest VC funds, with backing from Korea Venture Investment Corp., pension funds from Switzerland, Germany and the U.S., and from global family offices.
Vickers' track record includes hits such as Baidu.com, Focus Media, Asian Food Channel, Cambridge Real Estate Investment Trust, TWG Tea and Focus Media Holding.
"We are very excited to continue to back the SiSaf team and their groundbreaking technology and wanted to ensure that no time was lost due to COVID-19," said Finian Tan, chairman of Vickers Venture Partners.
In 2018, the VC company led SiSaf's $4.3 million interim funding round, which was also backed by Invest NI and Innovation Ulster Limited.
For the original story from DealStreetAsia, click here.
DealStreetAsia is a financial news site based in Singapore that focuses on private equity, venture capital and corporate investment activity in Asia, especially Southeast Asia, India and greater China. Nikkei owns a majority stake in the company.